Related references
Note: Only part of the references are listed.Phase II clinical trial of neoadjuvant trabectedin in patients with advanced localized myxoid liposarcoma
A. Gronchi et al.
ANNALS OF ONCOLOGY (2012)
A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study
G. Grignani et al.
ANNALS OF ONCOLOGY (2012)
Efficacy of imatinib mesylate for the treatment of locally advanced and/or metastatic tenosynovial giant cell tumor/pigmented villonodular synovitis
Philippe A. Cassier et al.
CANCER (2012)
Insulin Growth Factor-Receptor (IGF-1R) Antibody Cixutumumab Combined with the mTOR Inhibitor Temsirolimus in Patients with Refractory Ewing's Sarcoma Family Tumors
Aung Naing et al.
CLINICAL CANCER RESEARCH (2012)
Sorafenib in patients with metastatic gastrointestinal stromal tumors who failed two or more prior tyrosine kinase inhibitors: a phase II study of Korean gastrointestinal stromal tumors study group
S. H. Park et al.
INVESTIGATIONAL NEW DRUGS (2012)
One vs Three Years of Adjuvant Imatinib for Operable Gastrointestinal Stromal Tumor A Randomized Trial
Heikki Joensuu et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2012)
Anaplastic Lymphoma Kinase Aberrations in Rhabdomyosarcoma: Clinical and Prognostic Implications
J. Carlijn van Gaal et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Phase II Study of the Mammalian Target of Rapamycin Inhibitor Ridaforolimus in Patients With Advanced Bone and Soft Tissue Sarcomas
Sant P. Chawla et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Phase II Study of Imatinib in Advanced Chordoma
Silvia Stacchiotti et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
Winette T. A. van der Graaf et al.
LANCET (2012)
Sorafenib for Patients with Advanced Angiosarcoma: A Phase II Trial from the French Sarcoma Group (GSF/GETO)
Isabelle Ray-Coquard et al.
ONCOLOGIST (2012)
Predicting IGF-1R Therapy Response in Bone Sarcomas: Immuno-SPECT Imaging with Radiolabeled R1507
Emmy D. G. Fleuren et al.
CLINICAL CANCER RESEARCH (2011)
R1507, a Monoclonal Antibody to the Insulin-Like Growth Factor 1 Receptor, in Patients With Recurrent or Refractory Ewing Sarcoma Family of Tumors: Results of a Phase II Sarcoma Alliance for Research Through Collaboration Study
Alberto S. Pappo et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Preliminary Efficacy of the Anti-Insulin-Like Growth Factor Type 1 Receptor Antibody Figitumumab in Patients With Refractory Ewing Sarcoma
Heribert Juergens et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes
Patrick Schoffski et al.
LANCET ONCOLOGY (2011)
Biological Rationale and Current Clinical Experience With Anti-Insulin-Like Growth Factor 1 Receptor Monoclonal Antibodies in Treating Sarcoma Twenty Years From the Bench to the Bedside
David Olmos et al.
CANCER JOURNAL (2010)
Identification of the Receptor Tyrosine Kinase c-Met and Its Ligand, Hepatocyte Growth Factor, as Therapeutic Targets in Clear Cell Sarcoma
Ian J. Davis et al.
CANCER RESEARCH (2010)
Efficacy of Imatinib in Aggressive Fibromatosis: Results of a Phase II Multicenter Sarcoma Alliance for Research through Collaboration (SARC) Trial
Rashmi Chugh et al.
CLINICAL CANCER RESEARCH (2010)
Phase II study of oral masitinib mesilate in imatinib-naive patients with locally advanced or metastatic gastro-intestinal stromal tumour (GIST)
Axel Le Cesne et al.
EUROPEAN JOURNAL OF CANCER (2010)
Imatinib Mesylate in Advanced Dermatofibrosarcoma Protuberans: Pooled Analysis of Two Phase II Clinical Trials
Piotr Rutkowski et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab(CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study
David Olmos et al.
LANCET ONCOLOGY (2010)
Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study
David Thomas et al.
LANCET ONCOLOGY (2010)
Expression of MET in alveolar soft part sarcoma
Hyun Jung Jun et al.
MEDICAL ONCOLOGY (2010)
Crizotinib in ALK-Rearranged Inflammatory Myofibroblastic Tumor
James E. Butrynski et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Trabectedin in myxoid liposarcomas (MLS): a long-term analysis of a single-institution series
F. Grosso et al.
ANNALS OF ONCOLOGY (2009)
A Phase I Study of Single-Agent Nilotinib or in Combination with Imatinib in Patients with Imatinib-Resistant Gastrointestinal Stromal Tumors
George D. Demetri et al.
CLINICAL CANCER RESEARCH (2009)
Phase 1 dose-escalation study of oral tyrosine kinase inhibitor masitinib in advanced and/or metastatic solid cancers
J. C. Soria et al.
EUROPEAN JOURNAL OF CANCER (2009)
Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinib
M. Montemurro et al.
EUROPEAN JOURNAL OF CANCER (2009)
Efficacy and Safety of Trabectedin in Patients With Advanced or Metastatic Liposarcoma or Leiomyosarcoma After Failure of Prior Anthracyclines and Ifosfamide: Results of a Randomized Phase II Study of Two Different Schedules
George D. Demetri et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Pazopanib, a Multikinase Angiogenesis Inhibitor, in Patients With Relapsed or Refractory Advanced Soft Tissue Sarcoma: A Phase II Study From the European Organisation for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC Study 62043)
Stefan Sleijfer et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
The insulin-like growth factor system and sarcomas
Bart Rikhof et al.
JOURNAL OF PATHOLOGY (2009)
Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial
Ronald P. DeMatteo et al.
LANCET (2009)
Therapeutic potential of hepatocyte growth factor/scatter factor neutralizing antibodies: Inhibition of tumor growth in both autocrine and paracrine hepatocyte growth factor/scatter factor:c-Met-driven models of leiomyosarcoma
Chong-Feng Gao et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Complete response to imatinib in relapsing pigmented villonodular synovitis/tenosynovial giant cell tumor (PVNS/TGCT)
J. -Y. Blay et al.
ANNALS OF ONCOLOGY (2008)
Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: Proposal of new computed tomography response criteria
Haesun Choi et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Update of phase I study of imatinib (ST1571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group
AT van Oosterom et al.
EUROPEAN JOURNAL OF CANCER (2002)
Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas
M Van Glabbeke et al.
EUROPEAN JOURNAL OF CANCER (2002)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Share Paper
